fashion -WSS

fashion

author：focus 2025-09-28 01:35:45 - browse：2

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Flash flood warnings continue for parts of Missouri, Illinois

focus

WSS

Why Charlie Gard's case is so disturbing to Americans

St. Louis police protesters begin picking up checks in $4.9 million settlement

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Histogen: Failed biotech offers rare public look inside

Judge in Trump's classified documents case questions use of out

VC firm General Catalyst wants to buy a health system

leisure time

fashion

hotspot

In age of alternative facts, a scholarly course on calling out crap

Sana to lay off nearly a third of staff, de

Bright Health sells Medicare Advantage business to Molina

Chemotherapy drug shortage eases slightly but still widespread

United colonoscopy coverage change 'may cost lives,' doctors say

Restaurant meals are packed with calories, and we still keep eating them

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Tuberculosis patients need more than just free medication

Medical leaders decry Supreme Court decision on affirmative action

Bill would stop addiction treatment from triggering child abuse inquiry

knowledge

Flash flood warnings continue for parts of Missouri, Illinois

NFL doctors' conflicts of interest could endanger players, report says

In $4.8 billion deal, Bristol Myers Squibb to buy cancer player Mirati

Kansas bar where gunfire wounded 9 last month closes permanently

How CRISPR works, explained in two minutes

With heat waves through August, officials warn of health risks

Wikipedia

leisure time

focus

focus